Cognitive dysfunction and greater visit-to-visit systolic blood pressure variability

Journal of the American Geriatrics Society

Volumn 61, Issue 12, 2013, Pages 2168-2173

  Epstein, Noam U ^a   Lane, Kathleen A ^b   Farlow, Martin R ^b   Risacher, Shannon L ^b   Saykin, Andrew J ^b   Gao, Sujuan ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

cognition; hypertension; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE COMPONENT; ANIMAL FLUENCY; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY MASS; CLINICAL DEMENTIA RATING; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DEPRESSION; DIASTOLIC BLOOD PRESSURE; EPISODIC MEMORY; FEMALE; HUMAN; HYPERTENSION; HYPOTHESIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROIMAGING; OBSERVATIONAL STUDY; PSYCHOLOGIC TEST; REY AUDITORY VERBAL LEARNING TEST TOTAL SCORE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TRAIL MAKING TEST PART B; VASCULAR DISEASE; VEGETABLE FLUENCY;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS; SYSTOLE;

EID: 84890515024     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12542     Document Type: Article

References (26)

1. Brookmeyer R, Gray S, Kawas C,. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342.
2. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: Ten years later. Arch Neurol 2009; 66: 1447-1455.
3. Duyckaerts C, Delatour B, Potier MC,. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009; 118: 5-36.
4. Nelson PT, Braak H, Markesbery WR,. Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 2009; 68: 1-14.
5. Cherbuin N, Reglade-Meslin C, Kumar R, et al. Risk factors of transition from normal cognition to mild cognitive disorder: The PATH through life study. Dement Geriatr Cogn Disord 2009; 28: 47-55.
6. Ho AJ, Raji CA, Becker JT, et al. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging 2010; 31: 1326-1339.
7. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882-1891.
8. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's disease and cognitive decline. Evid Rep Technol Assess (Full Rep) 2010; 193: 1-727.
9. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
10. Rothwell PM,. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375: 938-948.
11. Morris JC,. Clinical dementia rating. Neurology 1993; 43: 2412-2414.
12. Partington JE, Leiter RG,. Partington's pathway test. Psychol Service Center Bull 1949; 1: 9-20.
13. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-1165.
14. Wechsler D,. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: The Psychological Corporation, 1981.
15. Rey A,. L'Examen Clinique en Psychologie. Paris: Presses Universitaires de France, 1964.
16. Cronk BB, Johnson DK, Burns JM,. Alzheimer's disease neuroimaging I. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2010; 24: 126-130.
17. Ravaglia G, Forti P, Lucicesare A, et al. Prevalent depressive symptoms as a risk factor for conversion to mild cognitive impairment in an elderly Italian Cohort. Am J Geriatr Psychiatry 2008; 16: 834-843.
18. Reitz C, Luchsinger J, Tang MX, et al. Effect of smoking and time on cognitive function in the elderly without dementia. Neurology 2005; 65: 870-875.
19. Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology 2007; 69: 1873-1880.
20. Koster A, Penninx BW, Bosma H, et al. Socioeconomic differences in cognitive decline and the role of biomedical factors. Ann Epidemiol 2005; 15: 564-571.
21. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162: 683-690.
22. Tervo S, Kivipelto M, Hänninen T, et al. Incidence and risk factors for mild cognitive impairment: A population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 2004; 17: 196-203.
23. Keary TA, Gunstad J, Poppas A, et al. Blood pressure variability and dementia rating scale performance in older adults with cardiovascular disease. Cogn Behav Neurol 2007; 20: 73-77.
24. McLaren A,. Heart Rate and Blood Pressure Variability: Association with White Matter Lesions and Cognitive Function Following Stroke. University of Newcastle upon Tyne, 2006 [on-line]. Available at http://hdl.handle.net/10443/ 965 Accessed September 16, 2013.
25. Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 2010; 375: 906-915.
26. Farlow M, Potkin S, Koumaras B, et al. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol 2003; 60: 843-848.